Binaytara shared a post on LinkedIn:
“Frontline Hodgkin lymphoma treatment just got a new standard. And the shift happened faster than almost anyone expected.
Following SWOG S1826 and FDA approval in March 2026, nivolumab-based frontline therapy has effectively replaced the previous default for advanced-stage classical Hodgkin lymphoma.
Dr. Hun Ju Lee, Associate Professor in the Department of Lymphoma and Myeloma at UT MD Anderson Cancer Center, breaks down what this means in practice: which patients benefit most from intensification, why PET-adapted de-escalation is still underused, and how to weigh consolidative radiation in patients who may live decades beyond their diagnosis.
Follow Binaytara for clinical oncology updates and expert analysis from leading specialists.”
Other articles about Binaytara on OncoDaily.